OncoMatch/Clinical Trials/NCT02479698
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Official title: Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection
Is NCT02479698 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies Allogeneic BK-specific Cytotoxic T-lymphocytes for acquired immunodeficiency syndrome.
Treatment: Allogeneic BK-specific Cytotoxic T-lymphocytes — This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02479698 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify